BioVie
- Company typePublic
- Founded2019
- HeadquartersBeverly, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
BioVie firmographics
Firmographics- Name
- BioVie
- Legal name
- BioVie Inc.
- Website
- https://bioviepharma.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BioVie industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where BioVie is headquartered
LocationHeadquarters
- HQ city
- Beverly
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioVie business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage pharmaceutical company. Revenue will come from commercialization of drug candidates bezisterim (NE3107) for Alzheimer's, Parkinson's, Long COVID and BIV201 for ascites/cirrhosis upon regulatory approval. No products currently approved or marketed.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
BioVie product offering
Product offeringCore offering
BioVie is a clinical-stage pharmaceutical company developing two drug candidates: bezisterim (NE3107), an orally administered anti-inflammatory and insulin-sensitizing small molecule being studied for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin delivered via a portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Neither candidate is yet approved or commercially marketed, so revenue will come from future commercialization upon regulatory approval.
Product overview
BioVie is a clinical-stage pharmaceutical company developing drug therapies for neurological, neurodegenerative, and liver diseases. The company's product portfolio consists of two main drug candidates: Bezisterim (NE3107), an oral anti-inflammatory insulin sensitizer being developed for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin for treating refractory ascites associated with liver cirrhosis. Both drug candidates target inflammatory pathways believed to be central to disease progression.
Differentiator
Problem solved
Functional benefit
Products and services
- Bezisterim (NE3107) BioVie's lead asset: a novel, orally administered small molecule that is both anti-inflammatory and insulin-sensitizing. It selectively inhibits inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators, including TNF-α, without inhibiting their homeostatic functions. Currently being studied for Alzheimer's disease, Parkinson's disease, and neurological symptoms of Long COVID.
- BIV201 A novel continuous infusion formulation of terlipressin delivered via a small, portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Holds US Orphan drug designation for ascites and hepatorenal syndrome, and FDA Fast Track status for ascites. Phase 2b data showed greater than 50% reduction in ascites fluid buildup.
Quantifiable outcome
- 68% slowing of cognitive decline after 6 months of bezisterim treatment in Alzheimer's patients
- +4 more outcomes
Companies that use BioVie
Customer profileSegments4 records
Ideal customer profiles3 records
BioVie technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BioVie partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Option Therapeutics (Spinout)coreBioVie plans to spin out its BIV201 ascites program into a newly filed public company called Option Therapeutics, needing to raise $25 million to fund a required Phase III trial after observing greater than 50% reduction in ascites fluid buildup in terminated Phase IIb data.
Scale indicators14 records
Recent moves7 records
Expansion highlights5 records
BioVie competitors and assessment
Company assessmentDirect peers
- Anavex Life Sciences: Clinical-stage NASDAQ-listed CNS biotech developing small molecules for Alzheimer's, Parkinson's, Rett syndrome, and other neurodegenerative indications. Highly comparable to BioVie in size, stage, mechanism novelty, and indication overlap.
- Cassava Sciences: Clinical-stage small-cap biotech developing simufilam for Alzheimer's disease. Comparable to BioVie in market cap range, single-asset CNS focus, and dependence on pivotal-stage data catalysts.
Emerging players
- Acumen Pharmaceuticals: Clinical-stage biotech developing sabirnetug (ACU193) for early Alzheimer's disease. Comparable as a small-cap, CNS-focused, anti-amyloid-mechanism competitor, though BioVie targets a non-amyloid mechanism.
- Vivoryon Therapeutics: European clinical-stage biotech developing small molecules targeting neuroinflammation in Alzheimer's (varoglutamstat). Closely parallels BioVie's inflammation-driven CNS hypothesis and pipeline stage.
- Prothena Corporation: Clinical-stage biotech developing protein-based therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable as a small-cap CNS-focused player, though operating with a different therapeutic modality.
- Axsome Therapeutics: CNS-focused biotech with FDA-approved products (Auvelity, Sunosi) in neurology and psychiatry. Comparable as a small-cap CNS commercial-stage peer, providing a benchmark for BioVie's potential transition from clinical to commercial stage.
- Cognition Therapeutics: Clinical-stage small-cap biotech developing CT1812 for Alzheimer's disease and dementia with Lewy bodies. Comparable to BioVie in market cap, stage, and CNS focus on neurodegenerative diseases.
Broad incumbents
- Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company that markets Terlivaz (terlipressin) — the FDA-approved formulation of the same active ingredient in BioVie's BIV201 — for hepatorenal syndrome. Direct competitive incumbent in BioVie's ascites franchise.
- Sage Therapeutics: CNS-focused biopharma with FDA-approved Zurzuvae (zuranolone) for postpartum depression. Comparable as a small-mid cap CNS company with approved and pipeline neurology/psychiatry assets, broader in scale and commercial maturity than BioVie.
- Denali Therapeutics: Clinical-stage CNS and lysosomal disease biotech developing therapies for Parkinson's, Alzheimer's, and ALS. Comparable indication overlap with BioVie, larger in scale, and a useful public-market reference for CNS biotech valuation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BioVie social profiles
Digital presenceBioVie financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioVie leadership team
Management profileNumber of profiles
Profiles12 records
BioVie funding detail
Funding detailFunding overview
Funding rounds9 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioVie M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioVie
What does BioVie do?
BioVie is a clinical-stage pharmaceutical company developing two drug candidates: bezisterim (NE3107), an orally administered anti-inflammatory and insulin-sensitizing small molecule being studied for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin delivered via a portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Neither candidate is yet approved or commercially marketed, so revenue will come from future commercialization upon regulatory approval.
Is BioVie a public or private company?
BioVie is a public company. It is classified as public and is currently operating.
When was BioVie founded?
BioVie was founded in 2019. It employs 11 to 50 people.
Where is BioVie based?
BioVie is headquartered in Beverly, United States, in the North America region.
How does BioVie make money?
One revenue line is on record: drug Development and Commercialization.
Who are BioVie's main competitors?
Direct peers on record are Anavex Life Sciences and Cassava Sciences. Emerging players are Acumen Pharmaceuticals, Vivoryon Therapeutics, Prothena Corporation, Axsome Therapeutics and Cognition Therapeutics. Broad incumbents are Mallinckrodt Pharmaceuticals, Sage Therapeutics and Denali Therapeutics.
Does BioVie have an API?
No public API is recorded for BioVie.
What industry is BioVie in?
BioVie's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.